| Quarterly Financial Information [Table Text Block] |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Tc99m tilmanocept sales revenue | | $ | — | | | $ | — | | | $ | — | | | $ | — | | | Tc99m tilmanocept license revenue | | | — | | | | 100 | | | | — | | | | — | | | Tc99m tilmanocept royalty revenue | | | — | | | | — | | | | — | | | | 9 | | | Grant and other revenue | | | 580 | | | | 512 | | | | 224 | | | | 386 | | | Gross profit | | | 580 | | | | 612 | | | | 224 | | | | 391 | | | Operating expenses | | | 3,728 | | | | 5,435 | | | | 2,609 | | | | 3,912 | | | Loss from operations | | | (3,148 | ) | | | (4,823 | ) | | | (2,385 | ) | | | (3,521 | ) | | Loss before income taxes | | | (4,319 | ) | | | (4,783 | ) | | | (2,317 | ) | | | (6,371 | ) | Benefit from (provision for) income taxes
| | | 1,454 | | | | 1,631 | | | | 776 | | | | 201 | | | Loss from continuing operations | | | (2,865 | ) | | | (3,152 | ) | | | (1,541 | ) | | | (6,170 | ) | | Gain (loss) from discontinued operations, net of tax | | | 88,446 | | | | (2,036 | ) | | | 151 | | | | 2,112 | | Net income (loss) attributable to common stockholders
| | | 85,581 | | | | (5,188 | ) | | | (1,390 | ) | | | (4,058 | ) | Loss per common share (basic)
| | | | | | | | | | | | | | | | | | Continuing operations | | $ | (0.02 | ) | | $ | (0.02 | ) | | $ | (0.01 | ) | | $ | (0.04 | ) | | Discontinued operations | | $ | 0.55 | | | $ | (0.01 | ) | | $ | — | | | $ | 0.01 | | | Attributable to common stockholders | | $ | 0.53 | | | $ | (0.03 | ) | | $ | (0.01 | ) | | $ | (0.03 | ) | Loss per common share (diluted)
| | | | | | | | | | | | | | | | | | Continuing operations | | $ | (0.02 | ) | | $ | (0.02 | ) | | $ | (0.01 | ) | | $ | (0.04 | ) | | Discontinued operations | | $ | 0.54 | | | $ | (0.01 | ) | | $ | — | | | $ | 0.01 | | | Attributable to common stockholders | | $ | 0.52 | | | $ | (0.03 | ) | | $ | (0.01 | ) | | $ | (0.03 | ) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Tc99m tilmanocept sales revenue | | $ | 9 | | | $ | 4 | | | $ | 18 | | | $ | 9 | | | Tc99m tilmanocept license revenue | | | 254 | | | | 246 | | | | 1,296 | | | | — | | | Grant and other revenue | | | 686 | | | | 917 | | | | 511 | | | | 1,022 | | | Gross profit | | | 947 | | | | 1,166 | | | | 1,821 | | | | 975 | | | Operating expenses | | | 4,705 | | | | 3,407 | | | | 2,731 | | | | 4,215 | | | Loss from operations | | | (3,758 | ) | | | (2,241 | ) | | | (910 | ) | | | (3,240 | ) | | Loss from continuing operations | | | (2,682 | ) | | | (817 | ) | | | (1,761 | ) | | | (2,118 | ) | | Gain (loss) from discontinued operations, net of tax | | | (1,004 | ) | | | (5,865 | ) | | | 1,702 | | | | (1,764 | ) | | Net loss attributable to common stockholders | | | (3,686 | ) | | | (6,682 | ) | | | (59 | ) | | | (3,882 | ) | Loss per common share (basic and diluted)
| | | | | | | | | | | | | | | | | | Continuing operations | | $ | (0.02 | ) | | $ | (0.01 | ) | | $ | (0.01 | ) | | $ | (0.01 | ) | | Discontinued operations | | $ | 0.00 | | | $ | (0.03 | ) | | $ | 0.01 | | | $ | (0.02 | ) | | Attributable to common stockholders | | $ | (0.02 | ) | | $ | (0.04 | ) | | $ | (0.00 | ) | | $ | (0.03 | ) | |